Alpelisib-Piqray Chinese name

Alpelisib (Alpelisib)-Piqray is a new approach to overcoming endocrine therapy resistance in HR-positive, HER2-positive breast cancer by inhibiting the PI3K enzyme. Patients with an identified genetic mutation in the PIK3CA gene experienced improved progression-free survival (PFS) after apelvis was combined with fulvestrant. These patients can be identified in real time with therascreen PIK3CA CDT to expedite treatment initiation.

AlpelisCommon names include Alpelisib, Alpelisib, Abolib, and Alpelisib, and it is sold under the trade name PIQRAY. When prescribing Apelix, physicians must be aware of unique drug adverse events, such as hyperglycemia, and be prepared for appropriate treatment. Blood glucose and/or FPG should be monitored as clinically indicated, at least twice a week until blood glucose or FPG drops to normal levels. Clinical trials of Apelvis in combination with other endocrine therapies are ongoing for the maintenance treatment of HR-positive, HER2-negative, PIK3CA-mutated breast cancer, as well as for other cancer types.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.